Scarica l'app Stockscreener
55.11
1.66%
0.90
Precedente Chiudi:
$54.21
Aprire:
$55
Volume 24 ore:
776.74K
Relative Volume:
1.19
Capitalizzazione di mercato:
$4.24B
Reddito:
$754.05M
Utile/perdita netta:
$73.06M
Rapporto P/E:
60.74
EPS:
0.9073
Flusso di cassa netto:
$164.23M
1 W Prestazione:
+6.84%
1M Prestazione:
+2.74%
6M Prestazione:
+31.21%
1 anno Prestazione:
+97.31%
Intervallo 1D:
$54.33
$55.99
Intervallo di 1 settimana:
$51.08
$55.99
Portata 52W:
$26.27
$59.87
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Nome
Kiniksa Pharmaceuticals International Plc
Settore
Telefono
(781) 431-9100
Indirizzo
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
55.11 | 4.24B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-09-29 | Iniziato | TD Cowen | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2024-05-03 | Iniziato | Wells Fargo | Overweight |
| 2020-06-29 | Reiterato | BofA Securities | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-12-12 | Reiterato | Wedbush | Outperform |
| 2018-06-19 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Kiniksa Pharmaceuticals International Plc Borsa (KNSA) Ultime notizie
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - Yahoo Finance
Kiniksa Pharmaceuticals International PLC - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Institutional Confidence - TradingKey
Granahan Investment Management LLC Buys 32,642 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Spruce Street Capital LP Purchases New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KNSA Q1 2026 Earnings: EPS Surges Past Estimates, Stock Edges HigherEBITDA Estimate Trend - newsline.com
KNSA Q1 2026 Earnings: EPS Surges Past Estimates, Stock Edges UpEarnings Revision Downgrade - newsline.com
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surpasses Estimates by Over 31%Earnings Growth Analysis - newsline.com
Castleark Management LLC Raises Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA: Record ARCALYST growth, robust pipeline, and key clinical catalysts drive future momentum - TradingView
Kiniksa Pharmaceuticals (KNSA) Edges Lower, Testing Key Support LevelsZero Gamma Level - newsline.com
ESSEX INVESTMENT MANAGEMENT CO LLC's Kiniksa Pharmaceuticals International PLC(KNSA) Holding History - GuruFocus
KNSA Q1 2026 Earnings: EPS Surges Past Estimates, Stock Gains 2.88%Analyst Earnings Estimate - newsline.com
219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA) - Stock Titan
BNP Paribas Financial Markets Has $34.31 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa (KNSA) director receives RSUs and options in equity grants - Stock Titan
Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant - Stock Titan
CEO-linked trust converts 900,000 Kiniksa (NASDAQ: KNSA) Class B shares - Stock Titan
Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares - Stock Titan
Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant - Stock Titan
Kiniksa (KNSA) director exercises RSUs and receives new option grant - Stock Titan
Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards - Stock Titan
Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives - Stock Titan
Kiniksa (KNSA) Q1 2026 Earnings Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plc Files Form 8-K Detailing Annual Meeting Results and Company Information - Minichart
Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates - The Globe and Mail
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41 - GuruFocus
Kiniksa Pharmaceuticals (KNSA) Declines 4.84% as Stock Tests Key Support ZoneSupport Level Bounce - The Legal Advocate
Kiniksa (NASDAQ: KNSA) investors approve board, PwC auditor roles and pay - Stock Titan
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surprises by 31.5% Despite Stock DeclineRevenue Breakdown Analysis - newsline.com
Kiniksa Pharmaceuticals Files 8-K Disclosing Waiver of Share Conversion Rights with Baker Brothers Life Sciences 9 - Minichart
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights - TipRanks
Baker Bros sets 49.9% voting cap in Kiniksa (NASDAQ: KNSA) - Stock Titan
Kiniksa (NASDAQ: KNSA) sets 49.9% voting cap for Baker Bros. conversions - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Holds Near Flat as Stock Consolidates Near Key LevelsBullish Pattern Stocks - The Legal Advocate
UBS Group AG Purchases 28,099 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Raises Revenue Guidance After Strong ARCALYST Growth - HarianBasis.co
Kiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53 - MSN
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
KNSA Q1 2026 Earnings: Strong EPS Beat Driven by Operational Efficiency and Product GrowthEarnings Power Value - thelegaladvocate.com
Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc Azioni (KNSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.23%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):